^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    NEDD8 activating enzyme inhibitor

    Related drugs:
    Apply
    Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT03772925)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    06/20/2019
    Primary completion :
    06/16/2025
    Completion :
    06/16/2025
    BCL2 • CD4
    |
    TP53 mutation • FLT3 mutation
    |
    pevonedistat (MLN4924) • Beleodaq (belinostat)
    Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver (NCT04175912)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    03/16/2020
    Primary completion :
    11/27/2023
    Completion :
    10/31/2025
    CD4 • UBE2M • NEDD8
    |
    carboplatin • paclitaxel • pevonedistat (MLN4924)
    Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCI-2018-00315) (NCT03479268)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/22/2018
    Primary completion :
    06/22/2025
    Completion :
    06/22/2025
    CCND1 • FCER2
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)
    Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy (NCI-2019-03212) (NCT03965689)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    04/16/2020
    Primary completion :
    09/07/2022
    Completion :
    03/20/2025
    BRAF • ALK • ROS1 • B2M • RAD51 • CD4 • NQO1 • NTRK • SLC7A11 • UBE2M • ATF3 • NAE1
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression
    |
    carboplatin • paclitaxel • pevonedistat (MLN4924)
    Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia (NCT03009240)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    03/08/2024
    Initiation :
    08/21/2017
    Primary completion :
    12/15/2024
    Completion :
    12/15/2024
    MIR155 • NFKB1
    |
    miR-155 expression • NFKB1 expression
    |
    decitabine • pevonedistat (MLN4924)
    Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCI-2018-03465) (NCT03862157)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/10/2024
    Initiation :
    02/27/2019
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA
    |
    NPM1 mutation • CEBPA mutation • PDGFRA rearrangement
    |
    Venclexta (venetoclax) • azacitidine • pevonedistat (MLN4924)
    Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma (ADVL1615) (NCT03323034)
    Phase 1
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    11/06/2023
    Initiation :
    01/11/2018
    Primary completion :
    09/30/2021
    Completion :
    09/22/2024
    AFP
    |
    temozolomide • irinotecan • pevonedistat (MLN4924)
    Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat (NCT04712942)
    Phase 2
    University of Leipzig
    Completed
    Last update posted :
    08/21/2023
    Initiation :
    01/01/2021
    Primary completion :
    01/31/2023
    Completion :
    01/31/2023
    KIT • NPM1 • CD34
    |
    NPM1 mutation
    |
    azacitidine • pevonedistat (MLN4924)
    Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT03745352)
    Phase 2
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    06/27/2023
    Initiation :
    05/20/2019
    Primary completion :
    08/19/2021
    Completion :
    08/19/2021
    CD4
    |
    azacitidine • pevonedistat (MLN4924)
    Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy (PEVOLAM) (NCT04090736)
    Phase 3
    PETHEMA Foundation
    Active, not recruiting
    Last update posted :
    09/10/2022
    Initiation :
    09/24/2019
    Primary completion :
    06/30/2023
    Completion :
    06/30/2023
    FLT3 • IDH1 • IDH2 • NPM1 • CD4
    |
    azacitidine • pevonedistat (MLN4924)
    Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS (NCI-2019-06910) (NCT03459859)
    Phase 1
    Justin Watts, MD
    Completed
    Last update posted :
    12/28/2021
    Initiation :
    05/21/2018
    Primary completion :
    06/25/2021
    Completion :
    06/25/2021
    CDT1
    |
    cytarabine • pevonedistat (MLN4924)
    A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes (PEVOBINE) (NCT04985656)
    Phase 2
    Takeda
    Withdrawn
    Last update posted :
    09/29/2021
    Initiation :
    10/01/2021
    Primary completion :
    01/08/2024
    Completion :
    11/08/2024
    CD4
    |
    pevonedistat (MLN4924) • Inqovi (decitabine/cedazuridine)
    MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma (NCT01415765)
    Phase 1/2
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    12/17/2019
    Initiation :
    07/15/2011
    Primary completion :
    01/07/2014
    Completion :
    01/07/2014
    CARD11
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • pevonedistat (MLN4924) • Neupogen (filgrastim) • cyclophosphamide intravenous